! j\1odern methods of fractionaúng plasma into its components are based on the pioneering work of Cohn and bis colleagues during the second world war. Since rhen world demand for plasma products has increased so that it now exceeds rhar for cellular components of blood. The concept that optimal use of plasma is acbieved by fractionarion is now firmly established, and a wide range of producrs is available for rherapeutic use. We shall consider all these producrs excepr albumin. .\\ost therapeutic plasma products are manufactured from pools of plasma derived from many thousands of donors. Although strenuous efforts are being made to achieve self sufficiency, the United Kingdom is still substantially dependent on imported products that origina te mainly from commercial companies in the U nited States. In the past the safety of imported products was interior to that of those made within the NHS, but Ibis is not now the case. .'\ll products made from large pools of donor plasma are derived from individually screened donors and made by processes that inactivate or remove (or both) any contaminating viruses. Although the risks of viral transmission are small, there can never be absolute assurance of freedom from risk. It should also be appreciated that there are few absolute indications for treatment with plasma and plasma products and that some widely used products are unlicensed and prescribed for a "named patient" or under "Crown immunity." Especially in acquired disorders, in which sound evidence of efficacy is usually weakest, clinicians should take careful account of these factors before treating patients and be aware that inappropriate use is wasteful of a scarce resource for which demand exceeds supply. 
F resh frozen plasma
Half lives of infused coagulation factors contained in fresh frozen plasma Fresh frozen plasma is obtained either by separation of plasma from whole blood or by plasmapheresis. In either case the plasma is frozen as rapidly as possible after collection to preserve labile coagulation factors. Despite its widespread use, firm indications for giving fresh trozen plasma are few. It is helpful in the treatment of congenital deficiencies of coagulation factors (for example, that of factor V) when there is no specific factor concentrate available. Used aggressively, sometimes with plasma exchange, it is valuable in patients with thrombotic thrombocytopenic purpura and similar syndromes. Fresh frozen plasma may be used for the reversal of the effects of oral anticoagulation associated with serious bleeding if factor IX or factor VII concentrates are not available and to correct depletion of coagulation factors in bleeding associated with thrombolytic treatment. Despite being widely advocated for patients with multiple coagulation defects (as in severe liver disease, disseminated intravascular coagulation, and patients who have had massive transfusions), the effect of fresh frozen plasma is poorly defined and its use should probably be confined to patients with severe abnormalities on coagulation testing. What is clear is chal if any benefit is to be obtained fresh frozen plasma must be given in adequate quantities and rapidly-perhaps four donor units (800 mI) over one to two hours, and then repeated. There is no justification for its use as a volume expander; synthetlc colloids are more effective, cheaper, and safer.
Half lives of coagulation factors may be shortened when there is increased rnnSlJmptian -far example, in disseminated intravascular coagulation or during thrombotic episodes.
Cryoprecipitate
Cryoprecipitate is prepared from fresh frozen plasma by slow thawing at 4-6°C. The resulúng precipitate ("cryo") is then separated from the supernatant and refrozen for storage. Cryoprecipitate contains factor VIII, fibrinogen, von Willebrand factor, factor XIII, and fibronectin in higher concentrations than they are found in plasma, and its preparation is normally the first step in plasma fractionation. When used directly it is . usual to thaw and pool 10-30 donor units for an adult patient, but the dose depends on the circumstances. In the past cryoprecipitate was sometimes preferred to factor VIII concentrate as it was thought to be safer because it was made from smaller pools of donor plasma, but this is no longer so since the advent of effective sterilisation procedures for concentrates.
Cryoprecipitate is used to promote haemostasis in various conditions, but which of its several components is functionally important is often uncertain and thismakes monitoring and assessment of dosage difficult. When used in van Willebrand's disease its content of high molecular weight multimers of van Willebrand factor mar be of key importance. This may also be the case in chronic renal failure and some congenital platelet disorders, in which there is good evidence that it corrects abnormal bleeding times and controls bleeding. Mainly anecdotal evidence suggests possible benefit in some patients with disseminated intravascular coagulation, advanced liver disease, and the microvascular bleeding syndrome associated with massive transfusion. The thera~utic efficacy of cryoprecipitate is clase de~ndent, so increased clases and re~ated treatment may be needed if initial treatment seems to raíl.
The drug desmopressin (DDA VP) has been shown to have a similar effect to cryoprecipitate for several conditions and is clearly preferablé lar reasons ofboth cost and safety when its effect is equal.
BMj VOLUME 300 F actor VIII .;:oncentrate is the therapeutic product of .::hoice for patients \\"ith haemophilia A :.tactor VIII deficiency) and has superseded fresh frozen plasma and cryoprecipitate in its management. It is now also preferred to c~.oprecipitate for reasons of safety) for most patients with \'on \X.illebrand's disease who require treatment with plasma products. Like most other concentrates it is supplied as a freeze dried powder that is reconstituted \\"ith a small volume of sterile water before intravenous injection. Factor VIII has a short halflife (about 12 hours in vivo), so repeated injections are nec:essary for a sustained effect.
Used appropriately factor VIII is of great benefit to haemophiliacs, for whom it may be regarded as an essential drug. It both prevents and stops bleeding, prevents crippling arthropathy, and-as many patients are able to treat themselves-allows them to lead normal lives. Although haemophilia A is a rafe disease, demand for factor VIII is the main force behind the world's plasma fractionation industry, and the economics of supply of all other plasma products are critically dependent on this demando Recombinant (synthetic) factor VIII has recently been introduced in clinical trials. Though it may take several years for it to become generally available, it has the potential for causing serious imbalances in the fractionation industry with possible adverse effects on the availability and pricing of other plasma products. The factor IX concentrate (prothrombin complex concentrate) that is made within the NHS contains coagulation factors IX, X, and 11, and it is used for the treatment of haemophilia B (factor IX deficiency) and congenital deficiencies of factors X and 11. Given with factor VII concentrate it is more effective than fresh frozen plasma in controlling the serious haemorrhage that can be caused by overdoses of anticoagulants and may sometimes be useful in treating the bleeding associated with advanced liver disease. I t should be appreciated, however, that in liver disease ít can correct only part of the overall haemostatic abnormality and carnes a risk of provoking disseminated intravascular coagulation. Used in high doses factor IX concentrate may result in thrombotic episodes. In an anempt to reduce the risk of such episodes, commercially made concentrates containing factor IX alone are undergoing clinical trial.
Occasionally it is used to treat patients with haemophilia A who have circulating antibodies (inhibitors) to factor VIII beca use of its supposed inhibitor bypassing activity. Commercial "activated" prothrombin complex concentrates arc also availablé. Factor IX l,;oncél1iraié al:;o ..:ontains the physiological coagulation inhibitor proteins C and S. Its use in the treatment of deficiencies of these proteins is, however, still undefined, and a commercially made protein C concentra te has recently become available for clinical trial. .,Von-specific ("nonnal") immunoglobulin is derived from the pooled plasma of non-selected donors and contains antibodies (O all the viruses prevalent in (he donor population. One of the main indications for its intramuscular use is in (he passive prophylaxis of hepatitis A. Preparations made for intravenous use have the advantage that much larger doses mav be given with minimal discomfort (o the patient. Intravenous immunoglob"ulin was introduced primarily for the treatmen( of congeni(al hypogammaglobulinaemia, bu( its range of application has now broadened considerably (o include immunomodula(ion, especially in some au(oimmune disorders. A particular indication is for some (ypes of immune (hrombocytopenic purpura in which high doses of intravenous immunoglobulin are used (O induce (usually short ferro) rises in the pla(elet count. Its moJe of action is not certain but probably includes blockage of (he mononuclear phagocytes. Its clinical uses are increasing rapidly, and it represents an important afea of growth in treatment with plasma produc(s.
Other plasma products Several other plasma products have recently become available, and there is little doubt that these concentrates are effective in raising subnormal concentrations of circulating plasma factors. Except in the rafe congenital deficiency states, however, convincing evi~nce of clinical benefit is generally weak, and indications remain ill defined. 
'ANY QUESTIONS
Running vast distances together with [he training necessary to do so is not a normal childhood activity. The influences that drive ciíklren into these extraordinary pursuits and panicularly the panicipation oí their parents is a much more interesting subject. This aside, ho~.ever, [he questioner has grounds on which to challenge the basis of This girl has almost certainly got familial hypercholesterolaemia. This can be confirmed by showing that the raised cholesterol concentration represents an increase in low density lipoprotein choles¡erol \calculated in mrnol/l as total cholesterol rninus high densit)'lipoprotein cholesterol minus triglyceride divided by 2. 2) and by showing a similar abnormaliry plus the presence of tendon xant~mas or premature coronar\' disease, or both, in a first degree relative. It is also worth while measuring-her concentrations of thyroid stimulating hormone and thyroxine to exclude hypothyroidism.
As regards treatment, the safest drug to add to her diet is an anion exchange resin such as cholestyramine or colestipol in a dose of one or two sachets twice daily. I would not recomrnend using ahuman menopausal gonado[rophin coenzyme A reductase inhibitor in a young girl, but ¡bis rnigh[ be considered in later life. The risk of developing premature vascular disease in women with heterozygous familial hypercholes[erolaernia is much less Iban that in men with [bis disorder as long as they do no[ smoke. -G R THOMPSON, consulranrphysician, London
In men and women with familia! hypercholesterolaemia and xan[homatoSls. A comparatIvo s[udv oí g"netlc and envtronmental factorsin 27-1 heterozygous cases. AI""o"/ero,,, 1976:24:441-50 ls Ihere an_v reason u'h_v children should nOI take par! in long distance running, sa_v 5000 metres or more)
What is the best overnight disinfectant for metallined artificial dentures?
Complete dentures should be cleaned thoroughly, not only to prevent the build up of stains and odours but also to remove denture plaque, which is a common cause of denture stomatitis. Eflicient plaque control of partial dentures is equally important to prevent caries in the remaining teeth and inflammation of the surrounding periodontal tissues. A good brushing technique will prevent the accumulatíon of plaque, but it is frequently necessarv to use a denture cleaning solution because brushes may not reach all areas.of the denture. Furthermore, many elderly patients find a brush difficult to manipula te efliciently.
Hypochlorite denture cleaners are effective in removing plaque.'; A brand marketed in the United Kingdom is Dentural, but there is a warning that tbis product should not be used for cleaning metal dentures. Studies thal we have undertaken in Leeds, however, do not indicate a rísk of corrosion of the common cobalt chrornium alloys when ímmersed in Dentural, provided that the manufacturer's recommended short immersíon cycle is followed. Dentures should be cleaned only with products specially designed for the purpose. To treat the infective cause of denture stomatitis dentures should be removed at night to help control plaque; very occasionally a fungicide will have to be prescribed.
There mav be mechanical and svstemic cause" of denture stomatitis. Mechanical ~auses include ill litti~g dentures and an unbalanced or a locked occlusion. Systemic factors include deliciencie" of iron, vitamin 8-12, and folic acid; diabetes mellltus; and anv dc:bilitating conditíon that predisposes to a fungal ínfection. -R \1 BASKFR. J,.¡ln lIf ¡he -')chilO! ,,( Dentlst!)', L ds '
Injuries sustained in sport may arise either from trauma or from overuse. Experience in the United States suggests that the current upsurge in the proportion of overuse injuries seen in children is attributable to their increased participation in organised sport. T endon rupture or muscle tears are unusual: rather it is injury to the epiphysis or apophysis or other rapidly growing tissue that is the principal concem in children. Damage at these sites may interfc:rewith growth leading to permanent deforInÍty caused, ior example. by bone shortening.
It is this concern that has led the ,\merican authorities to discourage children from runmng distances over 10 km and the Amateur Athletics .\ssociation to exclude juveniles Irom events longer than S km, But e,'id.:nce tha! long distance running contributes more to inju~' than any other sport is lacking. lndeed. the acti,'ity \\'ith the \\'orst record of all in Britain l' hor,.: ridmg. I Budlt.-Jur""n"'" lo .\Io"",.!, ond m",h,"¡' lur ,komn" J"nlur,,' .1 /",,"h.1 1>..., 1,,;-",4b [19] [20] [21] [22] [23] 2 Au",burg"r IlH Elah, ]M E,oluollun ul ,"""n prop"",..r, .I"",ur" ,ko"""," ., /""'1/;.., /).., 19~~,4U5b-9 3 (¡ho¡',bebat .\\, Gr...r (ir,;, Zonder HA. Th" eloca.:' ot d"nlur"-cl,,anslng o""nl' 1 P,,',lh.1 />"'1 1~~2~51;20 8.\\J VOl.l~.\\E 300
